Monday, February 23, 2015 6:43:12 AM
Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, today announced that Dr. Mark J. Murray, Tekmira's President and CEO, will present a company overview at the 2015 RBC Capital Markets' Healthcare Conference on Tuesday, February 24, 2015 at 12:05 – 12:30 pm (PT) / 3:05 pm – 3:30 pm (ET) at The New York Palace Hotel in New York.
Webcast Information
A live webcast of the corporate overview presentation can be accessed through the Investor Section of Tekmira's website at www.tekmira.com. The webcast will be available approximately 90 minutes after the event has taken place.
About Tekmira
Tekmira Pharmaceuticals Corporation is a biopharmaceutical company focused on advancing novel RNAi therapeutics and providing its leading lipid nanoparticle (LNP) delivery technology to pharmaceutical and biotechnology partners. Tekmira has been working in the field of nucleic acid delivery for over a decade, and has broad intellectual property covering its delivery technology. Further information about Tekmira can be found at www.tekmira.com. Tekmira is based in Vancouver, Canada and Seattle, USA.
Recent ABUS News
- Arbutus Reports First Quarter 2024 Financial Results and Provides Corporate Update • GlobeNewswire Inc. • 05/02/2024 11:30:00 AM
- Arbutus Announces Retirement of Chief Scientific Officer, Michael J. Sofia, PhD, Effective December 31, 2024 • GlobeNewswire Inc. • 05/02/2024 11:25:00 AM
- Arbutus to Report First Quarter 2024 Financial Results and Provide Corporate Update • GlobeNewswire Inc. • 04/18/2024 11:30:00 AM
- Arbutus Biopharma Announces Claim Construction Ruling in its Ongoing Patent Infringement Lawsuit Against Moderna • GlobeNewswire Inc. • 04/04/2024 12:30:49 PM
- Arbutus to Participate in Two Upcoming Investor Conferences • GlobeNewswire Inc. • 03/08/2024 12:30:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/05/2024 09:48:49 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/29/2024 12:31:15 PM
- Arbutus Reports Fourth Quarter and Year End 2023 Financial Results and Provides Corporate Update • GlobeNewswire Inc. • 02/29/2024 12:30:00 PM
- Arbutus to Report Fourth Quarter and Year End 2023 Financial Results and Provide Corporate Update • GlobeNewswire Inc. • 02/15/2024 12:30:00 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 09:38:59 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 03:48:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/06/2024 12:55:14 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/06/2024 12:55:02 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/06/2024 12:54:25 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/06/2024 12:54:09 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/08/2024 12:31:16 PM
- Arbutus Announces 2024 Corporate Objectives and Provides Financial Update • GlobeNewswire Inc. • 01/08/2024 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/04/2024 09:09:10 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 11/21/2023 01:00:24 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/09/2023 09:02:39 PM
- Arbutus to Present at Jefferies London Healthcare Conference • GlobeNewswire Inc. • 11/08/2023 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/07/2023 09:18:57 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/07/2023 12:31:16 PM
- Arbutus Reports Third Quarter 2023 Financial Results and Provides Corporate Update • GlobeNewswire Inc. • 11/07/2023 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/07/2023 12:16:12 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM